In vivo, an AOC targeting the TENB2 with siRNA targeting PPIB gene to target prostate cancer cells was dosed 24 mg/kg three times over 3 days by i.v administration into a mouse tumour model, and demonstrated around a 30% knockdown in expression of PPIB [143]. This evidence concerns the gene PPIB and prostate cancer.